Markers of peripheral blood lymphocyte activation in local and advanced gatrointestinal cancer patients

++ , CD8 + , CD38 + , CD95 + , CD95L and CD25 + cells in PB and sIL2R, TNFa and sTNFRI in serum. Results. The results showed an insufficiency of the inductor phase of T cell immune response due to a decreased number of CD4 + cells in advanced gastrointestinal cancer patients and compensatory activity of effector cells. Elevated levels of sIL2R and an increased number of CD95 + cells were observed in advanced gastrointestinal cancer patients. The level of TNFa and sTNFRI did not differ significantly in patients with local and advanced gastrointestinal cancer. Conclusions. The variability of apoptotic and activation marker expression of PB immunocompetent cells shows a difference in immune response at various stages of gastrointestinal cancer. Cellular or serological markers of PB immune cell activation may be useful for under-standing an individual reaction to treatment and for the prognosis of disease.

[1]  D. Amadori,et al.  Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2 , 2003, British Journal of Cancer.

[2]  F. Recchia,et al.  Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study. , 2002, International journal of oncology.

[3]  M. Caligiuri,et al.  Interleukin‐2 enhances the natural killer cell response to Herceptin‐coated Her2 / neu‐positive breast cancer cells , 2001, European journal of immunology.

[4]  L. Lourenço,et al.  Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. , 2001, Hepato-gastroenterology.

[5]  H. Pircher,et al.  Crucial Role of TNF-α in CD8 T Cell-Mediated Elimination of 3LL-A9 Lewis Lung Carcinoma Cells In Vivo1 , 2000, The Journal of Immunology.

[6]  M. Beckmann,et al.  CD95 ligand expression as a mechanism of immune escape in breast cancer , 2000, Immunology.

[7]  T. Whiteside.  Signaling defects in T lymphocytes of patients with malignancy , 1999, Cancer Immunology, Immunotherapy.

[8]  F. Shanahan,et al.  Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. , 1999, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[9]  S. Tsujitani,et al.  Serum Level of a Soluble Receptor for Interleukin-2 as a Prognostic Factor in Patients with Gastric Cancer , 1999, Oncology.

[10]  D. Adams,et al.  Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. , 1999, The American journal of pathology.

[11]  Y. Goltsev,et al.  Tumor necrosis factor receptor and Fas signaling mechanisms. , 1999, Annual review of immunology.

[12]  R. Siegel,et al.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.

[13]  D. Loukinov,et al.  Fas and Fas Ligand Expression on Human Peripheral Blood Leukocytes , 1998, Vox Sanguinis.

[14]  P. Krammer,et al.  Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[16]  B. Gansbacher,et al.  Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. , 1996, Immunology today.

[17]  Jan Tavernier,et al.  Human TNF mutants with selective activity on the p55 receptor , 1993, Nature.

[18]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Tartaglia,et al.  Two TNF receptors. , 1992, Immunology today.

[20]  S. Rosenberg,et al.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.

[21]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[22]  H. Holtmann,et al.  Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells. , 1988, Journal of immunology.

[23]  H. Holtmann,et al.  Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. , 1988, Journal of immunology.

[24]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo , 2022 .